Physician in lab reading screen

Advancing the Cutting Edge of Cancer Care

While cancer care has already made tremendous progress, further innovation and research are necessary to develop and implement the next generation of therapeutics, best practices, disease preventions and specialized treatments targeted to the precise needs of the patient. Investigative research, including both “wet” translational and laboratory research as well as “dry” population health and value-based research, provides the ability to identify, develop and study new innovations in a real health system setting. The AdventHealth Cancer Institute participates in approximately 175 clinical trials each year, making it one of the most active sites for this kind of research in all of Florida.

Recent News

Blood Image
Circulating Tumor DNA Testing (ctDNA) Could Transform the Management of Colorectal Cancer
HAI pump
Hepatic Arterial Infusion Pump Offers New Hope to Patients with Liver Metastases from Colorectal and Bile Duct Cancers
New AdventHealth Study Examines the Role of the Gut Microbiome in Efficacy of Immunotherapy Treatment for Gynecological Cancers
Cancer Research Unit
Leveraging Evidence-based Oncology Pathways to Inform Multidisciplinary Tumor Board Decisions in Melanoma
AdventHealth is First in Central Florida to Perform Innovative Procedure for Patients with Aggressive Brain Tumors

Upcoming Events

3 items. To interact with these items, press Control-Option-Shift-Right Arrow
  • August 13, 2022

    Pancreas Updates

    Wyndham Grand Orlando Resort Bonnet Creek

  • September 24-25, 2022

    ASCO Direct

    The Ritz-Carlton Orlando, Grande Lakes

  • November 9-11, 2022

    OCC 2022

    Lowes Portofino Bay Hotel at Universal Orlando

    Labs at AdventHealth Nicholson Center

Highlighted Cancer Trials

Through cancer trials, we hope to find new ways to improve patients’ cancer treatments and quality of life. Our clinical trials provide access to innovative and experimental therapies to patients with solid and circulating tumors, including through the National Cancer Institute’s Clinical Trials Network (NCTN). Our centralized clinical research team is comprised of research nurses, data managers, research assistants and regulatory coordinators.

View All Cancer Trials

3 items. To interact with these items, press Control-Option-Shift-Right Arrow
  • Now Enrolling

    Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC

    Principal Investigator: Carlos Alemany, MD

  • Now Enrolling

    A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

    Principal Investigator: Mohamedtaki Tejani, MD

  • Now Enrolling

    A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)

    Principal Investigator: Carlos Alemany, MD

AdventHealth Physicians Share The Latest Updates In Their Fields

2 items. To interact with these items, press Control-Option-Shift-Right Arrow.
  • What is the role of surgery in the era of systemic therapy for melanoma?

  • Advanced Treatments for Anal Cancer and Dysplasia

Dr. Mark Socinski
External Speaking Event

Dr. Mark Socinski Speaks at OncLive Virtual Event

AdventHealth Cancer Institute Executive Medical Director Dr. Mark Socinski recently spoke about Clinical Management of ALK + Advanced Non-small Cell Lung Cancer (NSCLC) as part of OncLive’s Targetable Gene Rearrangements in Advanced Lung Cancer: Optimized Testing and Management virtual event. Dr. Socinski reviewed results from recent clinical trials exploring optimal therapy for the ALK-positive population and specifically discussed alectinib, brigatinib and lorlatinib.

Hexagon Background Image
A doctor looking through a microscope

Nationally Ranked Cancer Experts

Our oncologists, surgeons and other specialists serve as principal and co-investigators for a broad array of clinical trials exploring new treatments for all types of cancer. They frequently present at national and international forums and participate in developing new diagnostic technologies, state-of-the-art surgical systems and novel cancer therapies. Learn about the physicians and learn about the latest discoveries here.